IRVINE, Calif.--(BUSINESS WIRE)--Cortex Pharmaceuticals, Inc. (AMEX:COR) has negotiated a five-year extension on a key milestone in its exclusive AMPAKINE® License Agreement with the University of California, Irvine (UCI). Under this Amendment, Cortex has extended the date for the filing of a New Drug Application in the US, or its equivalent in a foreign country, until October 10, 2012.
